FY2025 EPS Estimate for Exact Sciences Decreased by Analyst

Exact Sciences Corporation (NASDAQ:EXAS) – Leerink Partnrs lowered their FY2025 EPS estimates for Exact Sciences in a research report issued on Tuesday, November 4th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn $0.42 per share for the year, down from their previous forecast of $0.47. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q4 2025 earnings at $0.15 EPS and Q3 2026 earnings at $0.34 EPS.

Other analysts have also recently issued research reports about the company. Guggenheim lifted their price target on Exact Sciences from $70.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday. Benchmark raised their price objective on Exact Sciences from $60.00 to $75.00 and gave the stock a “buy” rating in a research note on Tuesday. Stifel Nicolaus upped their target price on Exact Sciences from $67.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday. UBS Group cut their price target on shares of Exact Sciences from $61.00 to $53.00 and set a “neutral” rating on the stock in a report on Thursday, August 7th. Finally, Barclays raised their price target on shares of Exact Sciences from $65.00 to $77.00 and gave the stock an “overweight” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $73.44.

Exact Sciences Trading Down 1.5%

NASDAQ:EXAS opened at $66.18 on Thursday. The company has a market capitalization of $12.53 billion, a P/E ratio of -12.19, a PEG ratio of 5.56 and a beta of 1.34. The company has a current ratio of 2.89, a quick ratio of 2.56 and a debt-to-equity ratio of 0.94. Exact Sciences has a 12 month low of $38.81 and a 12 month high of $72.81. The firm has a fifty day simple moving average of $58.09 and a 200-day simple moving average of $53.40.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.11. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The company had revenue of $850.74 million for the quarter, compared to the consensus estimate of $810.42 million. During the same quarter in the previous year, the firm earned ($0.21) EPS. Exact Sciences’s revenue was up 20.0% compared to the same quarter last year. Exact Sciences has set its FY 2025 guidance at EPS.

Insider Activity at Exact Sciences

In other Exact Sciences news, EVP Brian Baranick sold 2,858 shares of the company’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $70.08, for a total value of $200,288.64. Following the sale, the executive vice president owned 22,368 shares in the company, valued at approximately $1,567,549.44. This represents a 11.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director James Edward Doyle sold 2,000 shares of Exact Sciences stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total transaction of $120,000.00. Following the transaction, the director directly owned 57,962 shares of the company’s stock, valued at approximately $3,477,720. This trade represents a 3.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 6,343 shares of company stock valued at $382,688. 1.20% of the stock is owned by company insiders.

Institutional Trading of Exact Sciences

A number of hedge funds have recently added to or reduced their stakes in the company. Synovus Financial Corp purchased a new position in Exact Sciences in the third quarter valued at $252,000. Axxcess Wealth Management LLC acquired a new stake in shares of Exact Sciences during the 3rd quarter valued at about $216,000. Eagle Health Investments LP increased its stake in shares of Exact Sciences by 21.1% in the 3rd quarter. Eagle Health Investments LP now owns 270,950 shares of the medical research company’s stock valued at $14,824,000 after purchasing an additional 47,200 shares in the last quarter. M&G PLC increased its stake in shares of Exact Sciences by 3.3% in the 3rd quarter. M&G PLC now owns 198,968 shares of the medical research company’s stock valued at $10,943,000 after purchasing an additional 6,394 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D raised its holdings in Exact Sciences by 4.6% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 67,057 shares of the medical research company’s stock worth $3,669,000 after purchasing an additional 2,972 shares during the period. 88.82% of the stock is owned by hedge funds and other institutional investors.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.